Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{205686,
        author = {Harshad Haridas Katkar and Aniket Ramesh Shinde and Vishal Santosh Nalpe and Samarth Indrajeet Birajdar and Sachin Shivaji Rathod},
        title = {Neurotrophin Mimetics and Tropomyosin Kinase Receptors: A Futuristic Pharmacological Tool for Parkinson's Disease},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {1},
        pages = {8297-8303},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=205686},
        abstract = {The management of Parkinson's disease (PD) remains a significant challenge due to the lack of clinically proven disease-modifying therapies. Standard treatments focus almost entirely on replacing dopamine, which temporarily alleviates motor symptoms but fails to stop the ongoing loss of dopaminergic neurons. This review highlights the therapeutic potential of targeting neurotrophin pathways specifically Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) and their associated tropomyosin receptor kinase (Trk) receptors, TrkB and TrkA, to promote neuroprotection and neurorestoration.
Because natural neurotrophins have poor pharmacokinetic properties, such as a short half-life and an inability to cross the blood-brain barrier (BBB), current research is focused on developing small-molecule neurotrophin mimetics. This paper discusses the molecular mechanisms of these synthetic compounds, maps their intracellular signalling pathways, reviews preclinical data, and examines the clinical challenges faced by these advanced pharmacological tools.},
        keywords = {},
        month = {June},
        }